Analystreport

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Canaccord Genuity from $550.00 to $575.00. They now have a "buy" rating on the stock.

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com